Isotechnika Inc.

Advisory - Isotechnika to Announce Clinical Data From Phase III Psoriasis Trial

    Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. will announce preliminary 48 week clinical trial data  for the Company's Canadian Phase III psoriasis trial for its lead  immunosuppressive drug, ISA247, on Monday, March 20th at 8:00 a.m. EST/6:00  a.m. MST.

    Management will provide an overview of the preliminary 48 week Phase  III data following the release at 9:00 a.m. EST/ 7:00 a.m. MST. All  interested parties will be able to access the live web cast (listen only  mode) through our corporate Web site at www.isotechnika.com.

    About Isotechnika Inc.

    ----------------------

    Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in  medicinal chemistry and immunology, the Company is focused on the discovery  and development of novel immunosuppressive therapeutics that are safer than  currently available treatments. Its entrepreneurial management and world- class team of scientists are building a pipeline of immunosuppressive drug  candidates for treatment of autoimmune diseases and for use in the  prevention of organ rejection in transplantation. Isotechnika looks to  become the leader in development of immunosuppressant therapies.

    Isotechnika's lead compound, ISA247, is an immunosuppressant currently  in an extension protocol of a Canadian Phase III human clinical trial for  the treatment of moderate to severe psoriasis. In addition, ISA247 has  successfully completed a Phase IIa trial for kidney transplantation. The  Company also has an additional immunosuppressive compound in its drug  pipeline, TAFA93, which is in Phase I.

    In addition to the Company's drug pipeline, Isotechnika also has a diagnostic division, which includes the Helikit(R) and Diatest(R) breath  kits. The Helikit(R), a 13C urea breath test, is used for the detection of  H. pylori, a bacterium that infects a large portion of the population. The  Diatest(R), a 13C glucose breath test, is used to measure insulin resistance.

    Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol ISA. More information on Isotechnika can be found  at www.isotechnika.com.

    Forward-Looking Statements

    --------------------------

    This press release may contain forward-looking statements. Forward-  looking statements, including the Company's belief as to the potential of  its products, the Company's expectations regarding the issuance of  additional patents and the Company's ability to protect its intellectual  property, involve known and unknown risks and uncertainties, which could  cause the Company's actual results to differ materially from those in the  forward-looking statements. Such risks and uncertainties include, among  others, the availability of funds and resources to pursue research and  development projects, the ability to economically manufacture its products,  the potential of its products, the success and timely completion of  clinical studies and trials, the Company's ability to successfully  commercialise its products, the ability of the Company to defend its  patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of  others. Investors should consult the Company's quarterly and annual filings  with the Canadian commissions for additional information on risks and  uncertainties relating to the forward- looking statements. Investors are  cautioned against placing undue reliance on forward-looking statements.

    Trades on Toronto Stock Exchange - (TSX: ISA)

    www.isotechnika.com

    Archived images on this organisation are searchable through CNW Photo  Archive website at http://photos.newswire.ca. Images are free to  accredited members of the media.

    To request a free copy of this organisation's annual report, please  go to http://www.newswire.ca and click on Tools for Investors.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
For further information: Stephanie Gillis-Paulgaard, Director,
Corporate Communications, Isotechnika Inc., Phone: +1-780-909-4661,
Fax: +1-780-484-4105, E-mail: sgillis-paulgaard@isotechnika.com



Weitere Meldungen: Isotechnika Inc.

Das könnte Sie auch interessieren: